The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Use of comprehensive next-generation sequencing to identify pathogenic germline variants with therapeutic relevance in metastatic breast cancer.
 
Nicole Margo Grogan
No Relationships to Disclose
 
Yi-Mi Wu
No Relationships to Disclose
 
Dan R. Robinson
No Relationships to Disclose
 
James M. Rae
No Relationships to Disclose
 
Norah Lynn Henry
Research Funding - Abbvie (Inst); Pfizer (Inst)
 
Daniel F. Hayes
Stock and Other Ownership Interests - InBiomotion
Consulting or Advisory Role - Agendia; BioVica; Cellworks; Cepheid; Epic Sciences; Freenome; Oncocyte; Salutogenic Innovations; Xentigen
Research Funding - AstraZeneca (Inst); Lilly (Inst); Menarini Silicon Biosystems (Inst); Merrimack (Inst); Pfizer (Inst); Puma Biotechnology (Inst)
Patents, Royalties, Other Intellectual Property - Circulating Tumor Cell Capturing Techniques and Devices. Patent No.: US 8,951,484 B2. Date of Patent: Feb. 10, 2015. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Diagnosis and Treatment of Breast Cancer. Patent No. US 8,790,878 B2. Date of Patent: Jul. 29, 2014. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Royalties from licensed technology.; Title: A method for predicting progression free and overall survival at each follow-up timepoint during therapy of metastatic breast cancer patients using circulating tumor cells. Patent no. 05725638.0-1223-US2005008602.
Travel, Accommodations, Expenses - Menarini Silicon Biosystems
Other Relationship - Menarini; UpToDate
(OPTIONAL) Uncompensated Relationships - UpToDate
 
Michelle F. Jacobs
No Relationships to Disclose
 
Kara J. Milliron
Stock and Other Ownership Interests - InheRET
 
Bailey Hulswit
Consulting or Advisory Role - InheRET
 
Lauren E. Hipp
No Relationships to Disclose
 
Sofia Merajver
Employment - InheRET; InheRET
Leadership - InheRET
Stock and Other Ownership Interests - InheRET
 
Elena Martinez Stoffel
Research Funding - Cancer Prevention Pharmaceuticals (Inst)
 
Arul Chinnaiyan
Stock and Other Ownership Interests - Esanik; LynxDx; Oncopia Therapeutics; Tempus
Honoraria - BMS
Consulting or Advisory Role - Ascentage Pharma; EdenRoc Sciences; Esanik; LynxDX; Oncopia Therapeutics; Rappta Therapeutics; Tempus
Patents, Royalties, Other Intellectual Property - University of Michigan Patents
 
Erin Frances Cobain
Consulting or Advisory Role - AstraZeneca; Athenex; Ayala Pharmaceuticals; bioTheranostics; Immunomedics
Speakers' Bureau - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca